2 research outputs found
Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol
Cb2 is a novel protooncogene encoding the peripheral cannabinoid receptor.
Previous studies demonstrated that 2 distinct noncoding first exons exist:
exon-1A and exon-1B, which both splice to protein-coding exon-2. We
demonstrate that in retrovirally induced murine myeloid leukemia cells
with proviral insertion in Cb2, exon-1B/exon-2 Cb2 messenger RNA levels
have been increased, resulting in high receptor numbers. In myeloid
leukemia cells without virus insertion in this locus, low levels of only
exon-1A/exon-2 Cb2 transcripts were present and receptors could not be
detected. To elucidate the function of Cb2 in myeloid leukemia cells, a
set of in vitro experiments was carried out using 32D/G-CSF-R (granulocyte
colony-stimulating factor receptor) cells transfected with exon-1B/exon-2
Cb2 complementary DNA and a myeloid cell line carrying a virus insertion
in Cb2 (ie, NFS 78). We demonstrate that a major function of the Cb2
receptor is stimulation of migration as determined in a transwell assay.
Exposure of Cb2-expressing cells to different cannabinoids showed that the
true ligand for Cb2 is 2-arachidonoylglycerol (2-AG), which may act as
chemoattractant and as a chemokinetic agent. Furthermore, we observed a
significant synergistic activity between 2-AG and interleukin-3 or G-CSF,
suggesting cross-talk between the different receptor systems.
Radioactive-ligand binding studies revealed significant numbers of Cb2
receptors in normal spleen. Transwell experiments carried out with normal
mouse spleen cells showed 2-AG-induced migration of B220-, CD19-,
immunoglobulin M-, and immunoglobulin D-expressing B lymphocytes. Our
study demonstrates that a major function of Cb2 receptor expressed on
myeloid leukemia cells or normal splenocytes is stimulation of migration
The common viral insertion site Evi12 is located in the 5'-noncoding region of Gnn, a novel gene with enhanced expression in two subclasses of human acute myeloid leukemia.
The leukemia and lymphoma disease locus Evi12 was mapped to the noncoding region of a novel gene, Gnn (named for Grp94 neighboring nucleotidase), that is located immediately upstream of the Grp94/Tra1 gene on mouse chromosome 10. The Gnn gene is conserved in mice and humans. Expression of fusion constructs between GFP and Gnn cDNA isoforms in HEK-293 cells showed that Gnn proteins are located mainly in the cytoplasm. Immunoblotting experiments demonstrated the presence of multiple Gnn protein isoforms in most organs, with the lowest levels of expression of the protein detected in bone marrow and spleen. The Evi12-containing leukemia cell line NFS107 showed high levels of expression of a approximately 150-kDa Gnn isoform (Gnn107) that was not observed in control cell lines. Overexpression may be due to the viral insertion in Evi12. The Gnn107 protein is probably encoded by a Gnn cDNA isoform that is expressed exclusively in NFS107 cells and that includes sequences of TU12B1-TY, a putative protein with homology to 5'-nucleotidase enzymes. Interestingly, using Affymetrix gene expression data of a cohort of 285 patients with acute myeloid leukemia (AML), we found that GNN/TU12B1-TY expression was specifically increased in two AML clusters. One cluster consisted of all AML patients with a t(8;21) translocation, and the second cluster consisted of AML patients with a normal karyotype carrying a FLT3 internal tandem duplication. These findings suggest that we identified a novel proto-oncogene that may be causally linked to certain types of human leukemia